Main Content

Selected scientific papers authored by BPC Graduates

  • 2024

    - Dinh-Fricke AV, Hantschel O.Improving the pharmacokinetics, biodistribution and plasma stability of monobodies. Front. Pharmacol. 2024 Mar 15:1393112. doi: 10.3389/fphar.2024.1393112
    - Leyte-Vidal, A., Garrido Ruiz, D., DeFilippis, R., Leske, I. B., Rea, D., Phan, S., Miller, K. B., Hu, F., Mase, A., Shan, Y., Hantschel, O., Jacobson, M. P.,  Shah, N. P. (2024). BCR::ABL1 Kinase N-lobe Mutants Confer Moderate to High Degrees of Resistance to Asciminib. Blood. https://doi.org/10.1182/blood.2023022538.
    - Shirafkan F, Hensel L, Rattay K. Immune tolerance and the prevention of autoimmune diseases essentially depend on thymic tissue homeostasis. Front Immunol. 2024 Mar 20;15:1339714. doi: 10.3389/fimmu.2024.1339714.
    - Leske IB, Hantschel O. The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib. Leukemia. 2024 Jun 15. doi: 10.1038/s41375-024-02314-7.
    - Verhagen MP, Joosten R, Schmitt M, Välimäki N, Sacchetti A, Rajamäki K, Choi J, Procopio P, Silva S, van der Steen B, van den Bosch TPP, Seinstra D, de Vries AC, Doukas M, Augenlicht LH, Aaltonen LA, Fodde R. Non-stem cell lineages as an alternative origin of intestinal tumorigenesis in the context of inflammation. Nat Genet. 2024 Jun 20. doi: 10.1038/s41588-024-01801-y.
    - Leske IB, Hantschel O. The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib. Leukemia. 2024 Sep;38(9):2041-2045. doi: 10.1038/s41375-024-02314-7.
    - Zhou L, Pereiro MT, Li Y, Derigs M, Kuenne C, Hielscher T, Huang W, Kränzlin B, Tian G, Kobayashi K, Lu GN, Roedl K, Schmidt C, Günther S, Looso M, Huber J, Xu Y, Wiech T, Sperhake JP, Wichmann D, Gröne HJ, Worzfeld T. Glucocorticoids induce a maladaptive epithelial stress response to aggravate acute kidney injury. Sci Transl Med. 2024 Oct 2;16(767):eadk5005. doi: 10.1126/scitranslmed.adk5005. 

  • 2023

    - Sundaresan B, Shirafkan F, Ripperger K, Rattay K. The Role of Viral Infections in the Onset of Autoimmune Diseases. Viruses. 2023 Mar 18;15(3):782. doi: 10.3390/v15030782. 
    - Völkel S, Tarawneh TS, Sacher L, Bhagwat AM, Karim I, Mack HID, Wiesmann T, Beutel B, Hoyer J, Keller C, Renz H, Burchert A, Neubauer A, Graumann J, Skevaki C, Mack EKM. Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib. Front Med (Lausanne). 2023 May 24;10:1176427. doi: 10.3389/fmed.2023.1176427.
    - Verhagen MP, Joosten R, Schmitt M, Valimaki N, Sacchetti A, Rajamaki K, Choi J, Procopio P, Silva S, van der Steen B, van den Bosch TPP, Seinstra D, Doukas M, Augenlicht LH, Aaltonen LA, Fodde R. The origin of intestinal cancer in the context of inflammation. bioRxiv [Preprint]. 2023 Nov 1:2023.10.02.560432. doi: 10.1101/2023.10.02.560432. 

  • 2022

    - Schmidt N, Abendroth F, Vázquez O, Hantschel O. Synthesis of the l- and d-SH2 domain of the leukaemia oncogene Bcr-Abl. RSC Chem Biol. 2022 Jul 6;3(8):1008-1012. doi: 10.1039/d2cb00108j.
    - Hammoud MK, Dietze R, Pesek J, Finkernagel F, Unger A, Bieringer T, Nist A, Stiewe T, Bhagwat AM, Nockher WA, Reinartz S, Müller-Brüsselbach S, Graumann J, Müller R. Arachidonic acid, a clinically adverse mediator in the ovarian cancer microenvironment, impairs JAK-STAT signaling in macrophages by perturbing lipid raft structures. Mol Oncol. 2022 Sep;16(17):3146-3166. doi: 10.1002/1878-0261.13221.